Nurture Nature Found Group

South Korea's R&D focus in 2026 has shifted heavily toward in-vivo gene editing and CRISPR-Cas9 technologies.

Leading biotech firms such as ToolGen and GenKOre are generating meaningful commercial outcomes in treating rare genetic disorders and chronic conditions like dementia. In 2026, Korean researchers are particularly noted for "DNA-free" editing techniques, which reduce off-target risks by delivering preassembled proteins. Furthermore, the integration of AI-driven diagnostics (led by companies like Lunit) with genomic analysis has enabled Korean clinicians to predict patient responses to gene therapy with over 90% accuracy, creating a high-tech ecosystem where "Personalized Medicine" is a standard of care.